136 related articles for article (PubMed ID: 6973453)
1. Localized chemotherapy of Gardner's lymphosarcoma of C3H mice using combinations of carrier-sorbed antifolics and detoxicating tetrahydrofolates.
Motycka K; Slavík K; Balcarová A; Spacek P; Kubín M
Czech Med; 1981; 4(1-2):14-24. PubMed ID: 6973453
[TBL] [Abstract][Full Text] [Related]
2. Treatment of solid Gardner lymphosarcoma with methotrexate sorbed on 2-hydroxyethylmethacrylate polymer in combination with leukovorin.
Motycka K; Slavík K; Balcarbová A; Cihar R; Spacek P; Kubín M
Neoplasma; 1978; 25(2):217-25. PubMed ID: 306074
[TBL] [Abstract][Full Text] [Related]
3. Effect of methotrexate sorbed on modified 2-hydroxyethylmethacrylate carriers in mice of C3H strain with a solid Gardner lymphosarcoma.
Motycka K; Slavík ; kocovská A; Cihar R; Spacek P; Kubín M
Neoplasma; 1977; 24(3):271-6. PubMed ID: 578291
[TBL] [Abstract][Full Text] [Related]
4. Distribution and pharmacokinetics of methotrexate in localized chemotherapy of solid Gardner's lymphosarcoma.
Slavíková V; Motycka K; Slavík K; Spacek P; Cihar R; Balcarová A
Neoplasma; 1978; 25(2):211-6. PubMed ID: 580447
[TBL] [Abstract][Full Text] [Related]
5. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. II. Chemotherapy of Gardner lymphosarcoma with pea seed lectin-methotrexate derivative.
Bures L; Motycka K; Bostík J; Slavík K; Jirásek A
Neoplasma; 1986; 33(4):409-16. PubMed ID: 3762803
[TBL] [Abstract][Full Text] [Related]
6. The chemotherapy of C3H mice bearing Gardner lymphosarcoma with bovine fibrinogen-methotrexate derivative.
Motycka K; Slavík K; Dyr JE; Balcarová A; Vodrázka Z
Neoplasma; 1981; 28(1):3-10. PubMed ID: 6895104
[TBL] [Abstract][Full Text] [Related]
7. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
8. Effect of free and bovine fibrinogen-bound methotrexate and dibromoaminopterin on the dissemination of solid Gardner lymphosarcoma.
Motycka K; Dyr JE; Macáková A; Slavík K
Neoplasma; 1982; 29(2):197-204. PubMed ID: 6896744
[TBL] [Abstract][Full Text] [Related]
9. Treatment of C3H mice bearing solid Gardner lymphosarcoma with vaccine prepared from Corynebacterium parvum combined with methotrexate and Alexan.
Motycka K; Chudomel V; Bednár M; Bostík J
Arch Immunol Ther Exp (Warsz); 1984; 32(4):413-9. PubMed ID: 6549500
[TBL] [Abstract][Full Text] [Related]
10. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.
Bures L; Bostík J; Motycka K; Spundová M; Rehák L
Neoplasma; 1988; 35(3):329-42. PubMed ID: 3405341
[TBL] [Abstract][Full Text] [Related]
11. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum(II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection.
Sirotnak FM; Schmid FA; DeGraw JI
Cancer Res; 1989 Jun; 49(11):2890-3. PubMed ID: 2785847
[TBL] [Abstract][Full Text] [Related]
12. Effect of sequence of administration of methotrexate, leucovorin, and 5-fluorouracil on mammary tumor growth and survival in syngeneic C3H mice.
Heppner GH; Calabresi P
Cancer Res; 1977 Dec; 37(12):4580-3. PubMed ID: 303542
[TBL] [Abstract][Full Text] [Related]
13. Effect of methotrexate and folinic acid on skeletal growth in mice.
Iqbal MP; Ahmed M; Umer M; Mehboobali N; Qureshi AA
Acta Paediatr; 2003 Dec; 92(12):1438-44. PubMed ID: 14971796
[TBL] [Abstract][Full Text] [Related]
14. Organ distribution of fibrinogen-bound methotrexate in mice with Gardner lymphosarcoma.
Slavíková V; Dyr JE; Motycka K; Pristoupilová K; Holý P; Slavík K
Neoplasma; 1987; 34(3):269-76. PubMed ID: 3614463
[TBL] [Abstract][Full Text] [Related]
15. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
16. Control of solid tumor metastases with a high-molecular-weight derivative of methotrexate.
Chu BC; Whiteley JM
J Natl Cancer Inst; 1979 Jan; 62(1):79-82. PubMed ID: 281578
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
18. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
Samuels LL; Straw JA
Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Capizzi RL
Cancer Treat Rep; 1981; 65 Suppl 4():115-21. PubMed ID: 7049375
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment.
Chu BC; Howell SB
J Pharmacol Exp Ther; 1981 Nov; 219(2):389-93. PubMed ID: 6974776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
